journal article·2021-01Open access

Analysis of RNA m 6 A methylation regulators and tumour immune cell infiltration characterization in prostate cancer

Yue Zhao, Huimin Sun, Jianzhong Zheng, Chen Shao

Abstract

Potential roles of RNA N6-methyladenosine (m6A) modification in tumour microenvironment (TME) cell infiltration has been demonstrated in recent studies. Nonetheless, the mechanism of its regulation remains unknown and immunotherapy has been marginal in prostate cancer. We demonstrated the expression of different m6A regulators within prostate cancer related to genetic variation, alternative splicing (AS), tumour mutational burden (TMB) and TME. Unsupervised clustering and risk prediction model constructed by 24 m6A regulators could predict scores of TME and prostate cancer patients prognosis. T cells CD8 was the intersection of immune cells which are related to multiple biological processes, and the fraction of T cells CD8 strongly correlates with immune associated gene sets. m6A methylation modification and immune cells infiltration played a nonnegligible role in prostate cancer. Our study represents a step towards personalized immunotherapy for prostate cancer patients.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA modifications and cancer · Cancer-related molecular mechanisms research · Cancer-related gene regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Urology, School of Medicine, Xiang’an Hospital of Xiamen University, Xiamen University, Xiamen, China

References (32)

Show source-provided references
1. 10.3322/caac.2144210.3322/caac.21442 ↗
2. 10.1016/j.ucl.2017.07.00810.1016/j.ucl.2017.07.008 ↗
3. 10.3390/ijms1810207910.3390/ijms18102079 ↗
4. 10.1001/jama.2014.208510.1001/jama.2014.2085 ↗
5. 10.1158/1078-0432.CCR-16-300110.1158/1078-0432.CCR-16-3001 ↗
6. 10.1056/NEJMoa180961510.1056/NEJMoa1809615 ↗
7. 10.1186/s12935-017-0437-310.1186/s12935-017-0437-3 ↗
8. 10.1038/nmeth.333710.1038/nmeth.3337 ↗
9. 10.1186/s13059-016-1070-510.1186/s13059-016-1070-5 ↗
10. 10.1158/0008-5472.CAN-16-347810.1158/0008-5472.CAN-16-3478 ↗
11. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
12. 10.1038/nm.339410.1038/nm.3394 ↗
13. 10.1016/0092-8674(74)90153-610.1016/0092-8674(74)90153-6 ↗
14. 10.1038/nature1111210.1038/nature11112 ↗
15. 10.1007/s11684-018-0654-810.1007/s11684-018-0654-8 ↗
16. 10.1038/s41586-019-0916-x10.1038/s41586-019-0916-x ↗
17. 10.1186/1471-2105-14-710.1186/1471-2105-14-7 ↗
18. 10.1038/nature2134910.1038/nature21349 ↗
19. 10.1186/s12943-019-1109-910.1186/s12943-019-1109-9 ↗
20. 10.1038/s41419-017-0129-x10.1038/s41419-017-0129-x ↗
21. 10.18632/oncotarget.2336510.18632/oncotarget.23365 ↗
22. 10.2147/OTT.S22679610.2147/OTT.S226796 ↗
23. 10.1038/nature1934210.1038/nature19342 ↗
24. 10.3892/or.2016.502210.3892/or.2016.5022 ↗
25. 10.1016/j.ygyno.2017.11.02810.1016/j.ygyno.2017.11.028 ↗
26. 10.1177/096368972094665310.1177/0963689720946653 ↗
27. 10.1038/s41422-019-0226-810.1038/s41422-019-0226-8 ↗
28. 10.1126/science.aaa134810.1126/science.aaa1348 ↗
29. 10.1002/1878-0261.1234810.1002/1878-0261.12348 ↗
30. 10.1016/j.ccell.2015.03.00110.1016/j.ccell.2015.03.001 ↗
31. 10.1093/intimm/dxw01410.1093/intimm/dxw014 ↗
32. 10.1038/s41586-018-0130-210.1038/s41586-018-0130-2 ↗